Comparative Pharmacology
Head-to-head clinical analysis: ACTH versus ACTHAR GEL AUTOINJECTOR.
Head-to-head clinical analysis: ACTH versus ACTHAR GEL AUTOINJECTOR.
ACTH vs ACTHAR GEL (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTH (corticotropin) stimulates the adrenal cortex to release cortisol, corticosterone, aldosterone, and androgenic steroids. It binds to the melanocortin 2 receptor (MC2R) in the adrenal gland, activating adenylyl cyclase and increasing intracellular cAMP.
ACTHAR Gel (repository corticotropin injection) acts primarily by stimulating the adrenal cortex to secrete corticosteroids (cortisol, corticosterone, and aldosterone), which exert anti-inflammatory, immunosuppressive, and antiproliferative effects. The exact mechanism in specific indications (e.g., infantile spasms) is not fully understood but may involve modulation of the hypothalamic-pituitary-adrenal axis and direct effects on the central nervous system.
40-80 units intramuscularly or subcutaneously every 24-72 hours for chronic conditions; 25 units intravenously over 8 hours for diagnostic use.
Initial: 40-80 units intramuscularly or subcutaneously every 24-48 hours; maintenance: 20-40 units intramuscularly or subcutaneously every 48 hours. Titrate based on response.
None Documented
None Documented
15 minutes (intravenous); rapid clearance due to enzymatic degradation; clinical effect persists 2-4 hours due to steroidogenesis
The terminal half-life of exogenously administered ACTH is approximately 15 minutes; however, the duration of adrenal cortisol stimulation persists for 6-12 hours after IM administration due to prolonged absorption from the gel formulation.
Renal: <5% unchanged; hepatic metabolism via proteolysis; <1% biliary/fecal
ACTH (corticotropin) is metabolized by tissue peptidases; renal excretion accounts for <5% of unchanged drug. Biliary/fecal elimination is negligible.
Category C
Category C
Corticotropin
Corticotropin